Octreotide (Sandostatin and Sandostatin LAR Depot)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

  • Treatment of acromegaly 
  • For management of gastrointestinal neuroendocrine tumors (NETs), such as any of the following:
    • Treatment of severe diarrhea and flushing episodes associated with carcinoid tumors 
    • Prophylactic treatment to prevent carcinoid crises prior to surgery for carcinoid tumor 
    • To reverse life-threatening hypotension due to carcinoid crisis during induction of anesthesia
    • For the treatment of the profuse watery diarrhea associated with vasoactive intestinal polypeptide-secreting tumors (VIPomas)
    • Prophylactic treatment prior to surgery for functioning gastrinoma (Zollinger Ellison syndrome)
    • Prophylactic treatment prior to hepatic artery embolization for nonresectable multiple and hormone-secreting neuroendocrine tumors
  • Stabilization of blood glucose levels in persons with functioning islet cell tumors (insulinomas or glucagonomas)
  • To reduce the incidence and severity of the postoperative complications of high-risk pancreatic surgery
  • Treatment of chemotherapy and/or radiation therapy-induced diarrhea when oral anti-diarrheal medications such as loperimide have become ineffective
  • Treatment of severe secretory diarrhea associated with acquired immunodeficiency syndrome (AIDS) when anti-microbial or anti-motility agents have become ineffective
  • Treatment of acute bleeding and early rebleeding of gastroesophageal varices associated with cirrhosis when used in conjunction with endoscopic band ligation or sclerotherapy or alone, if ligation/sclerotherapy is not immediately available
  • Treatment of unresectable malignant thymoma that is refractory to standard chemotherapy
  • To reduce output from gastrointestinal (GI) or pancreatic fistulas
  • Management of persons with short bowel syndrome if daily intravenous fluid requirements are greater than 3 liters
  • Management of gastrointestinal symptoms (e.g. nausea, vomiting, and pain) of inoperable bowel obstruction in persons with far advanced cancer
  • Thyroid stimulating hormone (TSH) hypersecretion due to TSH secreting adenoma
  • Dumping syndrome following gastric resection refractory to dietary changes and the addition of fiber

Coverage is Not Authorized For:

  • Non-FDA approved indications, which are not listed above unless there is sufficient documentation of efficacy and safety in the published literature
  • Sandostatin LAR is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for
  • Acromegaly
  • Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors
  • Profuse watery diarrhea associated with VIP-secreting tumors

Dosing:

  • Acromegaly: 50 mcg SC/IV tid (Max 1500 mcg/day) Carcinoid tumor symptoms: 100-600 mcg/day SQ/IV in 2-4 divided doses (Max 1500 mcg/day) VIPomas: 200-300 mcg SQ/IV in 2-4 divided doses Range (150-750 mcg) Western Health Advantage Pharmacy and Therapeutics Committee Approved/Revised: May 2009 Reviewed: July 2011
  • Secretory diarrhea, GI or pancreatic fistulas, short bowel syndrome, gastrointestinal symptoms of inoperable bowel obstruction in persons with terminal cancer, TSH secreting adenoma, and dumping syndrome: 50-100 mcg SC/IV qd-tid (Max 1500 mcg/day)
  • Sandostatin LAR
  • Acromegaly: 20-40 mg IM LAR q 4 weeks (Max 40 mg q 4 weeks) Carcinoid tumor symptoms: 20-30 mg LAR IM q 4 weeks (Max 30 mg q 4 weeks) may decrease to 10 mg q 4 weeks after a period of 2 months on 20 mg q 4 weeks VIPomas: 20-30 mg LAR IM q 4 weeks (Max 30 mg q 4 weeks) may decrease to 10 mg q 4 weeks after a period of 2 months on 20 mg q 4 weeks Secretory diarrhea, GI or pancreatic fistulas, short bowel syndrome, gastrointestinal symptoms of inoperable bowel obstruction in persons with terminal cancer, TSH secreting adenoma, and dumping syndrome: Patients must be titrated to response with the short-acting product then converted to LAR

 

Last review date: December 2, 2013

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.